Twist BioscienceTWST
TWST
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
196% more call options, than puts
Call options by funds: $5.99M | Put options by funds: $2.02M
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
22% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 27
9% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 82
1% more funds holding
Funds holding: 243 [Q3] → 245 (+2) [Q4]
0% less capital invested
Capital invested by funds: $3.09B [Q3] → $3.08B (-$7.9M) [Q4]
5.23% less ownership
Funds ownership: 116.69% [Q3] → 111.46% (-5.23%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$40
1%
downside
Avg. target
$52
29%
upside
High target
$62
54%
upside
3 analyst ratings
2 positive
67%
0 neutral
0%
1 negative
33%
Scotiabank Sung Ji Nam 17% 1-year accuracy 4 / 24 met price target | 54%upside $62 | Sector Outperform Maintained | 4 Feb 2025 |
JP Morgan Rachel Vatnsdal 50% 1-year accuracy 8 / 16 met price target | 1%downside $40 | Underweight Maintained | 4 Feb 2025 |
Baird Catherine Ramsey 50% 1-year accuracy 8 / 16 met price target | 34%upside $54 | Outperform Maintained | 4 Feb 2025 |
Financial journalist opinion
Based on 3 articles about TWST published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
Positive
Zacks Investment Research
2 weeks ago
Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Business Wire
2 weeks ago
Twist Bioscience Offers Clonal Genes for Global Academic Researchers at Express Speed for No Extra Cost
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that, for a limited time, all Twist Express Genes orders placed by academic customers globally will be shipped in as few as four days* without incurring a premium for the rapid turnaround time. “At Twist, we recognize the increasing challenge within colleges, universities and research ins.
Neutral
Business Wire
1 month ago
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that its executives will participate in fireside chats at the following upcoming investor conferences: Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 in Boston, MA.
Neutral
Business Wire
1 month ago
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that it has granted a total of 123,024 equity awards, consisting of 72,394 restricted stock units (“RSUs”) and up to 50,630 performance stock units (“PSUs”), to 32 recently hired individuals, in each case as a.
Positive
Zacks Investment Research
1 month ago
Twist Bioscience (TWST) Upgraded to Buy: Here's What You Should Know
Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Finbold
1 month ago
Cathie Wood dumped Palantir to buy these biotech stocks
Ark Invest Management chief executive officer (CEO) Cathie Wood is a lauded yet controversial figure.
Negative
Seeking Alpha
1 month ago
Twist Bioscience: Valuation Is Weighing On The Stock
Twist Bioscience reported solid Q1 FY25 results, although this was insufficient to drive the company's share price higher. The demand environment remains challenging, and Trump's election has created additional uncertainty. The implementation of tariffs could actually be a tailwind for Twist, though. Express genes and NGS appear to be driving Twist's growth at the moment, and this seems likely to persist for the foreseeable future.
Neutral
Seeking Alpha
1 month ago
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer and Co-Founder Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Subbu Nambi - Guggenheim Securities Catherine Schulte - Baird Brendan Smith - TD Cowen Vijay Kumar - Evercore ISI Matt Larew - William Blair Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Sung-Ji Nam - Scotiabank Operator Good day. Thank you for standing by.
Negative
Zacks Investment Research
1 month ago
Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago.
Charts implemented using Lightweight Charts™